As of the latest market activity, Nuwellis, Inc. (NASDAQ: NUWE) continues trading on the Nasdaq after regaining compliance with the minimum bid price requirement, which helped the company avoid delisting. NUWE’s share price has been volatile and relatively low compared with past levels, reflecting challenges the company has faced with revenue and profitability even as it develops its medical device business and expands programs like pediatric ultrafiltration therapy. Recently, the company secured new patents and FDA clearance for product enhancements, which have briefly boosted sentiment around the stock, though investor caution remains due to financial performance and ongoing operational losses. Because micro-cap stocks like NUWE can move unpredictably, many investors watch news about clinical progress and regulatory milestones closely for potential impact on price